Werewolf Therapeutics (HOWL) Net Income (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Net Income of $7.0 million for Q2 2026, up 138.68% year-over-year from $2.9 million in Q2 2025, and up 148.99% on a QoQ basis from -$14.2 million in Q1 2026.
Werewolf Therapeutics (HOWL) Net Income (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Net Income for 7 years, with the latest figure at $7.0 million in Q2 2026.
- Net Income for Q2 2026 came in at $7.0 million, up 138.68% year-over-year; the trailing twelve-month figure through Jun 2026 was -$34.8 million (up 51.63% YoY), and the FY2025 annual result was -$144.2 million, down 7.04% from the prior year.
- Net Income climbed to $7.0 million in Q2 2026, from -$14.2 million in the prior quarter.
- Over five years, Net Income peaked at $7.0 million in Q2 2026 and troughed at -$19.0 million in Q4 2024.
- A 5-year average of -$12.9 million and a median of -$14.5 million in 2022 frame the typical range for Net Income.
- The widest annual swing landed in 2024, when Net Income slumped 260.91%; it then soared 138.68% in 2026.
- A 5-year view of Net Income shows it stood at -$12.0 million in 2022, then gained by 0.02% to -$12.0 million in 2023, then tumbled by 58.44% to -$19.0 million in 2024, then surged by 46.22% to -$10.2 million in 2025, then jumped by 168.08% to $7.0 million in 2026.
- Per Business Quant data, the three most recent Net Income figures were $7.0 million in Q2 2026, -$14.2 million in Q1 2026, and -$10.2 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | 6.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.96 Mn |
| Mar 31, 2026 | -14.21 Mn |
| Dec 31, 2025 | -11.78 Mn |
| Sep 30, 2025 | -17.37 Mn |
| Jun 30, 2025 | -19.59 Mn |
| Mar 31, 2025 | -18.26 Mn |
| Dec 31, 2024 | -20.31 Mn |
| Sep 30, 2024 | -16.77 Mn |
| Jun 30, 2024 | -18.31 Mn |
| Mar 31, 2024 | -16.19 Mn |
| Dec 31, 2023 | -12.00 Mn |
| Sep 30, 2023 | -8.28 Mn |
| Jun 30, 2023 | -5.07 Mn |
| Mar 31, 2023 | -10.88 Mn |
| Dec 31, 2022 | -12.00 Mn |
| Sep 30, 2022 | -11.95 Mn |
| Jun 30, 2022 | -14.88 Mn |
| Mar 31, 2022 | -15.33 Mn |
| Dec 31, 2021 | -17.92 Mn |
| Sep 30, 2021 | -13.74 Mn |